LEUKOTAC

Serial Number 87849391
Registration 6115761
700

Registration Progress

Application Filed
Mar 26, 2018
Under Examination
Approved for Publication
May 19, 2020
Published for Opposition
May 19, 2020
Registered
Aug 4, 2020

Trademark Image

LEUKOTAC

Basic Information

Serial Number
87849391
Registration Number
6115761
Filing Date
March 26, 2018
Registration Date
August 4, 2020
Published for Opposition
May 19, 2020
Drawing Code
4

Status Summary

Current Status
Active
Status Code
700
Status Date
Aug 4, 2020
Registration
Registered
Classes
005 042 044

Rights Holder

MEDIOLANUM FARMACEUTICI S.P.A.

03
Address
VIA SAN GIUSEPPE COTTOLENGO, 15
MILAN 20143
IT

Ownership History

ELSALYS BIOTECH

Original Applicant
99
LYON FR

ELSALYS BIOTECH

Owner at Publication
99
LYON FR

ELSALYS BIOTECH

Original Registrant
99
LYON FR

MEDIOLANUM FARMACEUTICI S.P.A.

New Owner After Registration #1
03
MILAN IT

Legal Representation

Attorney
Michelle P. Ciotola

Application History

37 events
Date Code Type Description Documents
Aug 4, 2025 REM1 E COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED Loading...
Jan 24, 2024 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Aug 4, 2020 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
May 19, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
May 19, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Apr 29, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Apr 14, 2020 CNSA O APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Apr 10, 2020 ERFR I TEAS REQUEST FOR RECONSIDERATION RECEIVED Loading...
Apr 10, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Apr 10, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Apr 3, 2020 GNFN O NOTIFICATION OF FINAL REFUSAL EMAILED Loading...
Apr 3, 2020 GNFR O FINAL REFUSAL E-MAILED Loading...
Apr 3, 2020 CNFR R FINAL REFUSAL WRITTEN Loading...
Feb 26, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Feb 26, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Feb 24, 2020 ERSI I TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED Loading...
Feb 24, 2020 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED Loading...
Feb 24, 2020 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED Loading...
Feb 24, 2020 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED Loading...
Feb 24, 2020 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED Loading...
Feb 24, 2020 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED Loading...
Aug 28, 2019 CNSI R SUSPENSION INQUIRY WRITTEN Loading...
Aug 28, 2019 GNS2 O NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED Loading...
Aug 28, 2019 GNSI S INQUIRY TO SUSPENSION E-MAILED Loading...
Feb 28, 2019 GNS3 O NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Loading...
Feb 28, 2019 GNSL S LETTER OF SUSPENSION E-MAILED Loading...
Feb 28, 2019 CNSL R SUSPENSION LETTER WRITTEN Loading...
Jan 17, 2019 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jan 17, 2019 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Jan 17, 2019 ALIE A ASSIGNED TO LIE Loading...
Jan 14, 2019 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 12, 2018 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jul 12, 2018 GNRT F NON-FINAL ACTION E-MAILED Loading...
Jul 12, 2018 CNRT R NON-FINAL ACTION WRITTEN Loading...
Jul 11, 2018 DOCK D ASSIGNED TO EXAMINER Loading...
Apr 2, 2018 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Mar 29, 2018 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceutical preparations for immuno-oncology and autoimmune disease; pharmaceutical preparations, namely, immunotherapy monoclonal antibodies for immuno-oncology and for the treatment of autoimmune diseases; veterinary preparations for immuno-oncology and autoimmune disease; veterinary preparations, namely, immunotherapy monoclonal antibodies for immuno-oncology and for the treatment of autoimmune diseases; biotechnological preparations for medical and veterinary use, namely, immunotherapy monoclonal antibodies for immuno-oncology and for the treatment of autoimmune diseases
Class 042
Research and consultancy in the field of biotechnology; research and development in the field of biotechnology; scientific and technical consultation, namely, engineering evaluations and appraisals in the fields of science and technology; scientific and technology research in the field of immuno-oncology and autoimmune disease; laboratory research and analysis services in the field of immuno-oncology and autoimmune disease; scientific chemistry, biology and biotechnology laboratories; scientific laboratory services; laboratory testing, research and development of new products for others; conducting clinical trials for others in the field of medicines, molecules and medical devices; medical laboratory analysis services relating to the treatment of persons; medical laboratory services, including sample analysis; medical laboratory analysis services
Class 044
Medical services; pharmaceutical advice

Classification

International Classes
005 042 044